PRODUCT OVERVIEW & COMPOSITION
Brand / Manufacturer: Bioniche Pharma
Active Ingredient: Methenolone Enanthate (100 mg per ml)
Pharmacological Class: Synthetic Anabolic-Androgenic Steroid (Long-acting Dihydrotestosterone / DHT derivative)
Bioniche Pharma Methenolone Enanthate 100 mg is a long-acting injectable anabolic steroid derived from dihydrotestosterone (DHT). Engineered with an enanthate ester to ensure steady therapeutic release, Bioniche Pharma Methenolone Enanthate delivers clean tissue-building properties without aromatic conversion into estrogen or $17\alpha$-alkylated hepatic strain.
CLINICAL PHARMACOLOGY & MECHANISM OF ACTION
Bioniche Pharma Methenolone Enanthate acts by selectively binding to intracellular androgen receptors, shifting systemic nitrogen balance toward active cellular protein synthesis. Because it is a non-aromatizable DHT derivative, Bioniche Pharma Methenolone Enanthate causes no estrogenic activity, eliminating risks of gynecomastia and subcutaneous water retention while promoting lean muscle tissue accretion.
INDICATIONS & CLINICAL USE
- Palliative management of advanced hormone-responsive breast carcinoma in postmenopausal female patients using Bioniche Pharma formulations.
- Therapeutic support during recovery and rehabilitation following severe physical trauma, major surgery, or catabolic states with Bioniche Pharma anabolic support.
- Adjunctive treatment in growth impairment disorders under specialized Bioniche Pharma therapeutic supervision.
CONTRAINDICATIONS
- Confirmed or suspected carcinoma of the male breast or prostate gland.
- Female breast carcinoma complicated by severe hypercalcemia (elevated blood calcium levels).
- Severe renal failure or advanced hepatic disease.
- Pregnancy and lactation due to serious risks of fetal harm and developmental toxicity.
- Known hypersensitivity to Bioniche Pharma Methenolone Enanthate, carrier oils, or inactive components in Bioniche Pharma products.
PRECAUTIONS & METABOLIC MONITORS
- Glycemic Monitoring: Anabolic steroids can alter insulin sensitivity and glucose tolerance. Diabetic patients undergoing Bioniche Pharma therapy should monitor blood or urine glucose levels closely, as antidiabetic medication dosages may require adjustment.
- Pediatric Caution: Extreme caution is required in pediatric patients administered Bioniche Pharma products due to heightened sensitivity to androgenic effects and potential premature epiphyseal closure.
- Lipid & Hepatic Surveillance: Routine monitoring of serum lipid profiles (HDL/LDL fractions) and periodic liver function parameters is recommended during Bioniche Pharma treatment.
ADVERSE REACTIONS
- Dermatological & Androgenic: Low incidence of mild androgenic effects including oily skin, acne vulgaris, increased facial or body hair growth (hirsutism), and aggravation of androgenetic alopecia (male pattern baldness) associated with Bioniche Pharma administration, which are typically dose-dependent.
- Gastrointestinal & Neurological: At higher dosages, central nervous system stimulation or gastrointestinal disturbances may occur during Bioniche Pharma therapy, including diarrhea, excitation, restlessness, or insomnia.
- Endocrine: Dose-dependent suppression of endogenous gonadotropin secretion with prolonged Bioniche Pharma administration.
DOSAGE & ADMINISTRATION
Dosing protocols for Bioniche Pharma Methenolone Enanthate must be individualized and administered via deep intramuscular injection under strict medical oversight:
- Adult Males: Typical therapeutic dosages of Bioniche Pharma Methenolone Enanthate range from 200 mg to 400 mg weekly.
- Adult Females: Recommended dosages generally range between 50 mg and 150 mg weekly of Bioniche Pharma Methenolone Enanthate to achieve optimal therapeutic benefits while minimizing virilization risks.
STORAGE & HANDLING
Store Bioniche Pharma injectable products in a cool, dry place away from direct light exposure and excess heat. Do not refrigerate or freeze Bioniche Pharma products. Keep strictly out of reach and sight of children.